Cart
sales@molnova.com
5J-4
CAS No. 827001-82-1
5J-4( 5J 4 | 5J4 )
Catalog No. M27803 CAS No. 827001-82-1
5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE). 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 105 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 146 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 367 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5J-4
-
NoteResearch use only, not for human use.
-
Brief Description5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE). 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.
-
Description5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE). 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.(In Vivo):5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of the infiltrated mononuclear cell in the CNS, and significantly decreased the population of infiltrated CD4+ population. 5J-4 reduced the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in the mouse model of inflammation.
-
In Vitro——
-
In Vivo5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt.5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) reduces the symptoms and delayed the onset of EAE. Animal Model:C57BL/6 mice (MOG35-55 peptide-immunized mice)Dosage:2 m/kg Administration:I.p., every alternate day for 30 days Result:Dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of infiltrated mononuclear cell into the CNS, and significantly decreased the population of infiltrated CD4+ population.
-
Synonyms5J 4 | 5J4
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCDK4|CDK6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number827001-82-1
-
Formula Weight312.34
-
Molecular FormulaC16H12N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc1ccc2c(NC(=S)NC(=O)c3ccco3)cccc2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Richard Paul Beckmann, et al. Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer. WO2017180389A1.
molnova catalog
related products
-
Levetiracetam
Levetiracetam(UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain.
-
Clevidipine
A dihydropyridine L-type calcium channel blocker, highly selective for vascular and has little or no effect on myocardial contractility or cardiac conduction.
-
YM-244769
YM-244769 is an effective inhibitor of Na+/Ca2+ exchange 3 (NCX3) with an IC50 of 18 nM. YM-244769 has efficient protective effects on neurons and kidneys.
